Stock OMGA OMEGA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Omega Therapeutics, Inc.

Equities

OMGA

US68217N1054

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
2.4 USD -0.83% Intraday chart for Omega Therapeutics, Inc. -10.28% -20.27%
Apr. 16 Omega Therapeutics CFO Joshua Reed to Depart MT
Apr. 09 Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control CI

Business Summary

Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.

Number of employees: 94

Sales per Business

USD in Million2022Weight2023Weight Delta
Programmable Epigenomic mRNA Medicines
100.0 %
2 100.0 % 3 100.0 % +49.25%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
2 100.0 % 3 100.0 % +49.25%

Managers

Managers TitleAgeSince
Mahesh Karande CEO
 Chief Executive Officer 51 19-05-31
Joshua Reed DFI
 Director of Finance/CFO 51 22-05-22
Sivakesava Sakhamuri CTO
 Chief Tech/Sci/R&D Officer - 20-12-31
Samir Padalkar CTO
 Chief Tech/Sci/R&D Officer - 21-04-30
Ling Zeng ADM
 Chief Administrative Officer 55 22-03-29
Thomas McCauley CTO
 Chief Tech/Sci/R&D Officer 55 19-06-30
Yan Moore CTO
 Chief Tech/Sci/R&D Officer 58 22-01-09

Members of the board

Members of the board TitleAgeSince
Luke Beshar BRD
 Director/Board Member 65 21-04-30
John Mendlein BRD
 Director/Board Member 64 19-12-31
Christian Schade CHM
 Chairman 63 23-07-09
Mary Szela BRD
 Director/Board Member 61 19-05-31
Richard Young BRD
 Director/Board Member 70 17-07-31
Michelle Werner BRD
 Director/Board Member - 23-08-27
Elliott Levy BRD
 Director/Board Member 64 21-02-28
Rainer Boehm BRD
 Director/Board Member 63 22-08-31
Mahesh Karande CEO
 Chief Executive Officer 51 19-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 55,154,985 50,558,255 ( 91.67 %) 0 91.67 %

Shareholders

NameEquities%Valuation
Flagship Pioneering
53.00 %
29,225,579 53.00 % 107 M $
Fidelity Management & Research Co. LLC
9.587 %
5,286,575 9.587 % 19 M $
HarbourVest Partners LLC
6.369 %
3,512,110 6.369 % 13 M $
State of Wisconsin Investment Board
3.368 %
1,857,265 3.368 % 7 M $
Vanguard Fiduciary Trust Co.
2.737 %
1,509,188 2.737 % 6 M $
Artal Group SA
2.400 %
1,323,530 2.400 % 5 M $
BlackRock Advisors LLC
2.394 %
1,320,206 2.394 % 5 M $
Blue Owl Healthcare Opportunities Advisors LLC
1.915 %
1,055,882 1.915 % 4 M $
CHI Advisors LLC
1.915 %
1,055,882 1.915 % 4 M $
Platinum Investment Management Ltd.
1.608 %
886,782 1.608 % 3 M $

Company contact information

Omega Therapeutics, Inc.

140 First Street Suite 501

02141, Cambridge

+

http://www.omegatherapeutics.com
address Omega Therapeutics, Inc.(OMGA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Omega Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.42 USD
Average target price
11 USD
Spread / Average Target
+354.55%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
OMEGA THERAPEUTICS, INC. Stock Omega Therapeutics, Inc.
-20.27% 133M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.42% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+1.97% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-14.19% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.82% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.55% 18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-4.07% 11.68B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.36% 11.6B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.20% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. OMGA Stock
  4. Company Omega Therapeutics, Inc.